Chong-Xian Pan
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA · University of California, Davis · UC Davis Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Chong-Xian Pan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:49 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07793578 · Immunotherapy Plus Capivasertib for Metastatic Bladder CancerVA Office of Research and Development · not yet recruiting · Advanced Urothelial Carcinoma · principal investigator
- Ph1/Ph2NCT05687721 · Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder CancerVA Office of Research and Development · withdrawn · Advanced Urothelial Carcinoma · principal investigator
- Ph1NCT05519241 · A Phase I Intravesical PPM Therapy for NMIBCVA Office of Research and Development · recruiting · Non-muscle-invasive Bladder Cancer · principal investigator
- Ph1/Ph2NCT02935205 · Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate CancerMamta Parikh · unknown · Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer · principal investigator
- Early Ph1NCT02077998 · Oxaliplatin in Treating Patients With Metastatic Breast CancerUniversity of California, Davis · completed · Stage IV Breast Cancer · principal investigator
- Early Ph1NCT01261299 · Clinical Study of Microdosing Carboplatin in Lung or Bladder CancerUniversity of California, Davis · terminated · Carcinoma, Non-Small-Cell Lung, Urinary Bladder Neoplasms · study chair
- Ph2NCT00814788 · Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate CancerUniversity of California, Davis · completed · Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- BCCMA: Translational research to improve the care of advanced bladder cancerI01BX006075 · VA · VA BOSTON HEALTH CARE SYSTEM · fiscal years 2023 to 2027Same name and institution; not confirmed by an ID
- A Phase I trial of cancer-targeting micelles for non-myoinvasive bladder cancerI01CX002247 · VA · VA BOSTON HEALTH CARE SYSTEM · fiscal years 2021 to 2026Same name and institution; not confirmed by an ID
- Preclinical studies of KRAS and EGFR mutations in lung cancer PDXsU54CA233306 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · fiscal years 2018 to 2022 · $200,000 awarded in 2022Same name and institution; not confirmed by an ID
- Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancerI01BX003840 · VA · VA BOSTON HEALTH CARE SYSTEM · fiscal years 2018 to 2021Same name and institution; not confirmed by an ID
- Targeted- and timed-releasing nanotherapeutics against leukemia stem cellsR01CA176803 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · fiscal years 2015 to 2019 · $239,589 awarded in 2019Same name and institution; not confirmed by an ID
- Paul Calabresi Career Development Award for Clinical Oncology (K12) at UC DavisK12CA138464 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · fiscal years 2018 · $786,082 awarded in 2018Same name and institution; not confirmed by an ID
- Development of targeting nanotherapeutics against bladder cancerI01BX001784 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · fiscal years 2014 to 2017Same name and institution; not confirmed by an ID
- DEVELOP ASSAY TO QUANT PLAT-DNA ADDUCTS & PREDICT RESPONSE TO CHEMOTHERAP41RR013461 · NCRR · UNIVERSITY OF CALIF-LAWRNC LVRMR NAT LAB · fiscal years 2008 to 2009 · $58,316 awarded in 2009Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Integrated Cancer Biology ProgramP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Wolf-Dietrich Heyer · fiscal years 2004 to 2026Named on NCT02935205, NCT02077998
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:49 UTC. The ranking covers the 200 most relevant of 272 PubMed records, and a shared surname and initials can bring in a namesake. All 272 on PubMed
- Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.N Engl J Med · 20085,322 citationsRCR 147.0
- 1,511 citationsRCR 39.4
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.N Engl J Med · 20211,334 citationsRCR 73.5
- REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.N Engl J Med · 2021527 citationsRCR 26.1
- Effect of valsartan on the incidence of diabetes and cardiovascular events.N Engl J Med · 2010505 citationsRCR 13.0
- 471 citationsRCR 19.2
- 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.J Hepatol · 2018363 citationsRCR 16.3
- Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies.J Clin Oncol · 2005250 citationsRCR 6.5
- Remimazolam tosilate in upper gastrointestinal endoscopy: A multicenter, randomized, non-inferiority, phase III trial.J Gastroenterol Hepatol · 2021198 citationsRCR 21.4
- 193 citationsRCR 16.8